Literature DB >> 32013849

Modulatory Nano/Micro Effects of Diabetes Development on Pharmacology of Primary and Secondary Bile Acids Concentrations.

Armin Mooranian1, Nassim Zamani1, Ryu Takechi2, Giuseppe Luna1, Momir Mikov3, Svetlana Goločorbin-Kon4, Bozica Kovacevic1, Frank Arfuso5, Hani Al-Salami1.   

Abstract

BACKGROUND: Recent studies have suggested that hyperglycaemia influences the bile acid profile and concentrations of secondary bile acids in the gut.
INTRODUCTION: This study aimed to measure changes in the bile acid profile in the gut, tissues, and faeces in type 1 Diabetes (T1D) and Type 2 Diabetes (T2D).
METHODS: T1D and T2D were established in a mouse model. Twenty-one seven-weeks old balb/c mice were randomly divided into three equal groups, healthy, T1D and T2D. Blood, tissue, urine and faeces samples were collected for bile acid measurements.
RESULTS: Compared with healthy mice, T1D and T2D mice showed lower levels of the primary bile acid, chenodeoxycholic acid, in the plasma, intestine, and brain, and higher levels of the secondary bile acid, lithocholic acid, in the plasma and pancreas. Levels of the bile acid ursodeoxycholic acid were undetected in healthy mice but were found to be elevated in T1D and T2D mice.
CONCLUSION: Bile acid profiles in other organs were variably influenced by T1D and T2D development, which suggests similarity in effects of T1D and T2D on the bile acid profile, but these effects were not always consistent among all organs, possibly since feedback mechanisms controlling enterohepatic recirculation and bile acid profiles and biotransformation are different in T1D and T2D. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Type 1 diabetes; balb/c mice; chenodeoxycholic acid; lithocholic acid; secondary bile acids; type 2 diabetes

Mesh:

Substances:

Year:  2020        PMID: 32013849     DOI: 10.2174/1389450121666200204115121

Source DB:  PubMed          Journal:  Curr Diabetes Rev        ISSN: 1573-3998


  5 in total

1.  Reduced Cytokine Tumour Necrosis Factor by Pharmacological Intervention in a Preclinical Study.

Authors:  Armin Mooranian; Jacqueline Chester; Edan Johnston; Corina Mihaela Ionescu; Daniel Walker; Melissa Jones; Susbin Raj Wagle; Bozica Kovacevic; Thomas Foster; Momir Mikov; Hani Al-Salami
Journal:  Biomolecules       Date:  2022-06-23

Review 2.  The potential role of lactulose pharmacotherapy in the treatment and prevention of diabetes.

Authors:  Natural Chu; James Ling; He Jie; Kathy Leung; Emily Poon
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-15       Impact factor: 6.055

3.  Taurine Grafted Micro-Implants Improved Functions without Direct Dependency between Interleukin-6 and the Bile Acid Lithocholic Acid in Plasma.

Authors:  Armin Mooranian; Corina Mihaela Ionescu; Susbin Raj Wagle; Bozica Kovacevic; Daniel Walker; Melissa Jones; Jacqueline Chester; Thomas Foster; Edan Johnston; Sanja Kojic; Goran Stojanovic; Momir Mikov; Hani Al-Salami
Journal:  Biomedicines       Date:  2022-01-06

Review 4.  Biguanide Pharmaceutical Formulations and the Applications of Bile Acid-Based Nano Delivery in Chronic Medical Conditions.

Authors:  Melissa Jones; Corina Mihaela Ionescu; Daniel Walker; Susbin Raj Wagle; Bozica Kovacevic; Jacqueline Chester; Thomas Foster; Edan Johnston; Jafri Kuthubutheen; Daniel Brown; Marcus D Atlas; Momir Mikov; Armin Mooranian; Hani Al-Salami
Journal:  Int J Mol Sci       Date:  2022-01-13       Impact factor: 5.923

5.  The Effects of Primary Unconjugated Bile Acids on Nanoencapsulated Pharmaceutical Formulation of Hydrophilic Drugs: Pharmacological Implications.

Authors:  Armin Mooranian; Thomas Foster; Corina M Ionescu; Louise Carey; Daniel Walker; Melissa Jones; Susbin Raj Wagle; Bozica Kovacevic; Jacqueline Chester; Edan Johnstone; Jafri Kuthubutheen; Daniel Brown; Marcus D Atlas; Momir Mikov; Hani Al-Salami
Journal:  Drug Des Devel Ther       Date:  2021-10-23       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.